Kornimate/medical-research-clean huggingface dataset:
china antiretroviral treatment adherence for life

Conditions: HIV Infections

Summary: this study focuses on collecting and analyzing quantitative data related to adherence to antiretroviral treatment from patients in dali, china, over a one-year time-frame and generating preliminary data on an intervention designed to improve adherence to antiretroviral treatment among the study population.

this study is a continuation of "adherence for life (afl): phase i: exploratory research" (h-25203), which focused on collecting and analyzing qualitative data on adherence to antiretroviral treatment (art) among hiv-positive patients in dali, yunnan province, china. like phase i, the afl pilot study (phases ii and iii) will be a collaborative effort between us researchers based in boston, ma and chinese researchers based in beijing and dali. the current study, phases ii and iii, will focus on collecting and analyzing qualitative and quantitative data related to adherence to art over a one-year time-frame and generating preliminary data on an intervention designed to improve adherence to art among the study population. the questionnaires used in these phases of the study will draw on the results of phase i as well as standardized instruments adapted to the chinese context. the specific aims of the study are as follows: (1) to determine the best surrogate measure of art adherence among the study population; (2) to determine art adherence rates in this population; (3) to analyze the relationship between adherence factors and measured adherence rates; and (4) to generate preliminary effectiveness data on an intervention that makes use of electronic drug monitors (edm) to improve art adherence.

Eligibility criteria:
inclusion criteria: * patients who are 18 years of age or older, currently on antiretroviral treatment or about to begin it, live in the study catchment area, and are willing to provide informed consent. exclusion criteria: * persons below the age of 18 years, persons who are not currently on or about to start antiretroviral treatment, persons who live outside the study catchment area, or person not willing to provide informed consent.

Keywords: hiv antiretroviral treatment adherence intervention china adherence to antiretroviral treatment treatment experienced
the impact of pain on depression outcomes

Conditions: Pain; Depression

Summary: this study is a secondary data analysis of three of largest randomised controlled trials (rcts) of behavioural activation (ba) for older people with depression in the united kingdom (uk) primary care. the analysis will aim to explore the impact of pain on depression outcomes of older people receiving ba and potentially identify sub-groups of people who may not respond as well to treatment.

previous findings have indicated that pain might be an important barrier in depression treatment both with antidepressant medication and in a united states (us) collaborative care model using problem solving therapy and antidepressant medication. it is unknown, however, if pain impacts depression outcomes of older adults in a collaborative care (cc) framework focusing on a brief psychological intervention of ba. collectively casper, casper plus (+) and shard are three of the largest pragmatic, multi-centre randomised controlled trials (rct) of ba for older adults in uk primary care with low mood and depression. the purpose of this secondary data analysis is, therefore, to explore if pain moderates (modifies) the effect of ba on depression outcomes in older adults, potentially identifying subgroups of older adults who may not respond as well to ba.

Eligibility criteria:
inclusion criteria: * patients who participated in casper, casper + or shard study exclusion criteria: * anyone who did not consent into one of the three studies above

Keywords: older adults behavioural activation
effectiveness of n-acetyl cysteine, acetyl l- carnitine and medicated paraffin oil in aluminium phosphide poisoning

Conditions: the Study Focus to Improve the Standard of Care Used for Aluminuim Phosphide Poisoning and to Save Patients With the Minimal Organ Damage

Summary: aluminium phosphide is a pesticide used in developing countries to prevent rodents and pests from spoiling the harvested grains. it is presented as tablets which can be administered accidently to humans or for committing suicide. this pesticide is fatal even in small concentration as mortality rate can reach 75- 100% of cases. in this study researchers tried to add some supplements to the routine treatment to improve and decrease the fatality rate.


Eligibility criteria:
inclusion criteria: * all adult patients with history of acute intoxication with alp presented to the poison control center of ain-shams university hospitals during the period of the study exclusion criteria: 1. patients less than 18 2. patients presented with delay time exceeding 12 hours after acute intoxication. 3. patients with history of cardiac, renal or hepatic diseases. 4. patients who show hypersensitivity to nac, alcar or paraffin oil.

Keywords: n-acetyl cysteine acety l- carnitine paraffin oil aluminium phosphide
preoperative antibiotics for carpal tunnel release surgery

Conditions: Carpal Tunnel Syndrome

Summary: this is a clinical trial to determine how effective antibiotics administered prior to endoscopic carpal tunnel release surgery are in preventing surgical site infections.

study participants will be randomized to a prophylactic iv antibiotic treatment arm (vancomycin or cefazolin) or a placebo iv saline solution. subjects will be monitored following surgery for surgical site infections.

Eligibility criteria:
inclusion criteria: * high probability (\>12 points) on the carpal tunnel-6 diagnostic aide * recommendation for carpal tunnel release * capable of providing informed consent/lar to act on subject's behalf exclusion criteria: * patients allergic to both penicillin/cephalosporins and vancomycin * patient immobilized with splint or cast * unwilling unable to provide informed consent * children under the age of 18

Keywords: endoscopic carpal tunnel release prophylactic antibiotics
safety of cultured allogeneic adult umbilical cord derived mesenchymal stem cell intravenous infusion for lupus

Conditions: Lupus

Summary: this trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of lupus

studies have shown that stem cell treatment is safe and efficacious for the treatment of lupus. this patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells (uc-mscs) for the treatment of lupus. patients with lupus will receive a single intravenous infusion of uc-mscs. the total dose will be 100 million cells. patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy. for patients with more severe disease an autologous t-cell vaccine will be utilized created from the patient's own cells obtained by apheresis.

Eligibility criteria:
inclusion criteria: * diagnosis of lupus * understanding and willingness to sign a written informed consent document exclusion criteria: * active infection * active cancer * chronic multisystem organ failure * pregnancy * clinically significant abnormalities on pre-treatment laboratory evaluation * medical condition that would (based on the opinion of the investigator) compromise patient's safety. * continued drug abuse * pre-menopausal women not using contraception * previous organ transplant * hypersensitivity to sulfur

Keywords: lupus lupus arthritis stem cell treatment
does vibration therapy induce higher than normal bone strains and strain rates than those experienced during habitual daily activities

Conditions: Osteoporosis

Summary: the overall aim of this study is to test the hypothesis that vibration exercise can induce higher than normal bone strains and strain rates than are experienced during habitual locomotor activities. the investigators plan to study healthy young volunteers to: 1. determine the relationship between tibial bone strain and * the frequency and amplitude of vibration therapy * a range of habitual locomotor activities; 2. determine the transmission of vibrations during vibration therapy, in terms of * amplitude attenuation and phase shift of positional coordinates and accelerations at anatomic landmarks along the lower leg and other skeletal sites * the relationship between these and different frequencies and amplitudes of vibration therapy; 3. determine the muscle power in the lower limb associated with various habitual locomotor activities and its relationship to the measured tibial bone strain. the investigators subsequently hope to use the data captured in this experiment to develop a qct-based finite element (fe) model of the human lower limb (tibia, fibula and foot). the investigators will then validate this model in relation to the characteristics (amplitude and phase shift) of the measured tibial bone strain and transmission of vibrations to the different anatomical landmarks during vibration therapy.


Eligibility criteria:
inclusion criteria: * male or female volunteers, ages 18 to 50 years * generally healthy, as determined by review of medical history and physical exam * ambulatory * willing and physically able to undergo all study procedures * bmd (measured by dxa) at the lumbar spine and hip within ± 2 sd of the young normal range * bmi \< 30 exclusion criteria: * previous diagnosis of osteoporosis * history of fracture of the spine, pelvis, leg or foot * history of bone or joint disorders affecting the shoulders, spine, pelvis, legs or feet (e.g. arthritis, congenital hip dislocation, spinal spondylolisthesis) * ongoing conditions or diseases known to cause secondary osteoporosis * malabsorption syndromes (e.g. coeliac or crohn's disease) * known disorders of calcium metabolism * known history of thyroid disease * osteomalacia * paget's disease * diabetes * history of cancer within the previous 5 years * epilepsy * ongoing conditions or use of medications that may impair vision or balance * use of the following medications within the previous 2 years * bisphosphonates * fluoride (except use for oral hygiene) * strontium * teriparatide * other bone agents (e.g. serms, isoflavones, hrt, calcitonin etc) * steroids * alcohol abuse or illicit drug use * pregnancy or currently trying to conceive (women only) * inability to give informed consent * known hypersensitivity to the antibiotic penicillin or cephalosporins * known hypersensitivity to the local anaesthetic lignocaine.

Keywords: fracture anabolic vibration strain gauge focus - osteoporosis
study of efficacy and safety of ligelizumab in adolescents and adults with chronic inducible urticaria who remain symptomatic despite treatment with h1- antihistamines

Conditions: Chronic Inducible Urticaria

Summary: this was a placebo controlled, phase 3 study designed to evaluate the efficacy and safety of ligelizumab in participants with chronic inducible urticaria who are inadequately controlled with h1-antihistamines

there are currently no approved therapies for patients with cindu who remain symptomatic despite treatment with h1-antihistamines. the purpose of this study was to establish efficacy and safety of ligelizumab (qge031) over placebo in participants with chronic inducible urticaria (cindu) who remain symptomatic despite treatment with h1 antihistamine.

Eligibility criteria:
inclusion criteria: * confirmed cindu diagnosis (as per guidelines) for symptomatic dermographism, cold urticaria or cholinergic urticaria for ≥ 4 months. * diagnosis of cindu (symptomatic dermographism, cold urticaria or cholinergic urticaria) inadequately controlled with h1-ah at local label approved doses at the time of randomization, as defined by all of the following: * positive response (i.e development of symptoms) to triggers despite treatment with h1-ah * positive response (i.e. development of symptoms) to provocation test on day of randomization * participants must be able to physically perform the protocol defined provocation test specific to the participant's cindu. * cholinergic urticaria participants must show sweating in performing the pulse-controlled ergometry test on day of randomization. participants with anhidrosis must not be included. * willing and able to complete a daily symptom ediary as per protocol requirement and adhere to the study visit schedules exclusion criteria: * history of hypersensitivity to any of the study drugs or its components or to drugs of similar chemical classes or to the provocation test or items used in provocation tests * participants who have concomitant csu at screening * participants who have a familial form of the target cindu that is being considered for the participant's inclusion in this study * participants having a more defined other form of inducible urticaria than the target cindu that is being considered for the participant's inclusion in this study * diseases, other than chronic inducible urticaria, with urticarial or angioedema symptoms such as urticarial vasculitis, erythema multiforme, cutaneous mastocytosis (urticaria pigmentosa) and hereditary or acquired angioedema (eg, due to c1 inhibitor deficiency). * any other skin disease associated with chronic itching that might influence, in the investigator's opinion, the study evaluations and results (eg, atopic dermatitis, bullous pemphigoid, dermatitis herpetiformis, senile pruritus, etc.) or skin diseases associated with only wheals and no itch e.g asymptomatic dermographism * prior exposure to ligelizumab, omalizumab and or other anti-ige therapies

Keywords: ligelizumab anti-ige cindu chronic inducible urticaria symptomatic dermographism cold urticaria cholinergic urticaria urticaria itch hives
frailty assessment in vascular hot clinic setting - feasibility and prognostic value

Conditions: Frailty; Frail Elderly Syndrome; Surgery

Summary: a single-centre prospective study of feasibility assessing the suitability of introducing routine frailty screening in a controlled, and reproducible, outpatient department setting for vascular surgery patients. this study will also perform head-to-head comparisons of the prognostic value of five frailty assessment tools, selected based on the previous demonstration of their popularity and familiarity within the speciality, their designs being based on different theories of frailty and that some are endorsed by local healthcare police. inter-user variability (patient self assessment and clinician assessment will also be compared).

this single-centre prospective cohort study of feasibility, is conducted in a rapid-referral vascular surgery clinic, serving a population of 2 million. capax adults (\>18years), attending clinic for any reason are eligible for inclusion. five frailty assessments are completed at the clinic by patient (rockwood clinical frailty scale \[cfs\] and frail nondisabled questionnaire \[find\]), clinician (cfs, health care improvement scotland frail scale and 'initial clinical evaluation') and researcher (11-item modified frailty index, mfi-11). consistent with feasibility objectives, outcome measures include recruitment rates, frailty assessment completion rates, time-to-complete assessments and inter-rater variability. electronic follow-up at 30-days and 1-year will assess home-time and mortality as prognostic indicators. patients treated surgically/endovascularly will undergo additional 30-day and 1-year post-operative follow-up, outcome measures include: surgical procedure, mortality, complications (according to clavien-dindo classification), length-of-stay, readmission rates, non-home discharge, home-time, higher social care requirements on discharge and amputation-free survival. prognostic value will be compared by area under receiver operator characteristic (roc) curves. continuous outcome variables will be analysed using spearman's rank correlation coefficient. inter-user agreement will be compared by percentage agreement in cohen's kappa coefficient.

Eligibility criteria:
inclusion criteria: * adults (aged 18 years or older) * attending vascular hot clinic exclusion criteria: * lacking capacity to provide informed consent * parent clinical team feel frailty assessment not suitable * non-english speaker without qualified translator present * prisoners
open-label steroid reduction study of adalimumab with methotrexate in patients with active rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: the purpose of the study is to evaluate the clinical efficacy of scheduled versus free reduction of steroid treatment in patients with active ra treated with adalimumab + mtx


Eligibility criteria:
inclusion criteria: * subject is age 18 or older and in good health (investigator discretion) with a recent stable medical history * subject has a diagnosis of rheumatoid arthritis as defined by the 1987-revised acr criteria exclusion criteria: * subject considered by the investigator, for any reason, to be an unsuitable candidate for the study * female subject who is pregnant or breast-feeding or considering becoming pregnant
a trial to assess the effects of liraglutide on gallbladder emptying in overweight and obese subjects.

Conditions: Metabolism and Nutrition Disorder; Obesity

Summary: this trial is conducted in europe. the aim of this trial is to investigate the effects of liraglutide on gallbladder emptying in overweight and obese subjects.


Eligibility criteria:
inclusion criteria: * male or female, aged 18-64 years (both inclusive) at the time of signing informed consent * body mass index (bmi) equal to or above 27.0 kg/m\^2 * stable body weight (less than 3 kg self-reported change during the previous 3 months) * ultrasound assessment of gallbladder volume of an acceptable quality at screening, as judged by the investigator exclusion criteria: * female who is pregnant, breast-feeding or intends to become pregnant or is of child-bearing potential and not using adequate contraceptive methods (intrauterine devices or hormonal contraception (oral contraceptive pills, implants, transdermal patches, vaginal rings or longacting injections)) * history of gastrointestinal surgery or other medical procedure precluding gallbladder emptying assessment (appendectomy is allowed) or any significant digestive disease per the judgement of the investigator * history of pancreatitis (acute or chronic) or any gallbladder disease (incl. gallstones, gallbladder sludge, or polyps) * any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol
text message based maintenance intervention

Conditions: Mental Disorders

Summary: the study presents findings from a randomized clinical trial evaluating the effects of text messages encouraging short emotion regulation exercises on the course of psychopathological symptoms after inpatient treatment for depression. in this context, the study also compares the effectiveness of standardized versus personalized text messages.

introduction: the importance of aftercare and maintenance intervention to reduce psychopathology, prevent relapses and stabilize the effects of inpatient cognitive behavioral therapy is well proven. in order to attain a high reachability rate among the patients, simple, quick and low cost methods should be used. modern communication technologies, such as mobile phones provide this opportunity. therefore, the current study explores how modern communication technologies can be used as a support system in psychotherapy to realize a reduced psychopathology. methods: a total of 150 patients participated in a transdiagnostical 6-weeks text messaging maintenance intervention. the text messages were based on emotion regulation skills. the effectiveness of different variants of the text messages was studied in a randomized controlled trial, comparing the impact on the patient's psychopathological outcome to receiving personalized text messages versus standardized text messages.

Eligibility criteria:
inclusion criteria: * good knowledge of the german language * owning a mobile phone exclusion criteria: * brain damage * personality disorders

Keywords: maintenance intervention text messages emotion regulation
amyloid-β clearance mechanisms in alzheimer's disease

Conditions: Alzheimer's Disease (AD)

Summary: the focus of this study is to examine the protein-plaque clearance (aß) in relation to the blood-brain-barrier, the glymphatic system, brain lymphatic system and enzymatic degradation. in order to achieve this aim the investigators intend to study participants with a subjective cognitive decline, mild cognitive impairment and a mild alzheimer's disease.

in this study, the investigators want to examine the different mechanisms of the accumulation and the clearance of aß- deposits with imaging methods. one focus of the study is an improved characterisation of a blood-brain-barrier disorder (which seems to have an impact on the aß-accumulation). another main aim is to provide an improved mechanistic clearance model, which integrates crucial components such as the recently proposed cerebral glymphatic and lymphatic pathways, and which addresses the interaction between the different components and their individual contribution to aβ removal from the brain. a possible connection between sleep and an altered transport mechanism will be analysed. the prospective study cohort (n \~60) will include patients with mild cognitive impairment, mild clinical ad and subjective cognitive decline. all study participants will undergo a detailed clinical and neuropsychological assessment according to a standardised protocol (i.a. mri, pet, csf, actigraphy). follow-up assessments will not be performed in the present project, but are planned in a subsequent study, pending further funding.

Eligibility criteria:
inclusion criteria: * diagnosis of amnestic mci or ad dementia or clinical normal * able to provide written informed consent * unchanged pharmacotherapy within 4 days prior to the study specific assessments * fluent in german exclusion criteria: * unable to give informed consent or has a legal guardian * other severe mental disorder, e.g. schizophrenia or bipolar affective disorder * clinically relevant depression * acute suicidality * current alcohol, drug or medication abuse * history of severe traumatic brain injury within 3 months prior to inclusion * structural lesions of the basal ganglia or brain stem * severe neurological disorder including (but not limited to) epilepsy, systemic disorders, stroke, repeated transient ischaemic attacks, increased brain intracranial pressure, normal pressure hydrocephalus * severe medical disorders including (but not limited to) heart failure, respiratory failure, uncontrolled severe arterial hypertension * electronic implants (e.g. cardiac pacemaker) or other mri contraindication * renal failure \> stage 3 (gfr \< 30 ml/min) * pregnancy * unresolved malignancies within two years prior to inclusion * severe current infections or other chronic or systemic disorders * other circumstances which preclude participation based on the investigator's judgement

Keywords: alzheimer's disease mild cognitive impairment sleep actigraphy blood-brain-barrier amyloid-β clearance mechanisms